Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice by Wilke, Carlo et al.
Article
Neurofilaments in spinocerebellar ataxia type 3:
blood biomarkers at the preataxic and ataxic stage
in humans and mice
Carlo Wilke1,2 , Eva Haas3,4, Kathrin Reetz5,6, Jennifer Faber7,8, Hector Garcia-Moreno9,10,
Magda M Santana11, Bart van de Warrenburg12, Holger Hengel1,2, Manuela Lima13, Alessandro Filla14,
Alexandra Durr15, Bela Melegh16, Marcella Masciullo17, Jon Infante18, Paola Giunti9,10,
Manuela Neumann2,19, Jeroen de Vries20, Luis Pereira de Almeida11 , Maria Rakowicz21,
Heike Jacobi8,22, Rebecca Schüle1,2, Stephan A Kaeser1,2, Jens Kuhle23, Thomas Klockgether7,8,
Ludger Schöls1,2, SCA3 neurofilament study group‡, Christian Barro23,†, Jeannette Hübener-Schmid3,4,†
& Matthis Synofzik1,2,†,*
Abstract
With molecular treatments coming into reach for spinocerebellar
ataxia type 3 (SCA3), easily accessible, cross-species validated
biomarkers for human and preclinical trials are warranted, partic-
ularly for the preataxic disease stage. We assessed serum levels of
neurofilament light (NfL) and phosphorylated neurofilament heavy
(pNfH) in ataxic and preataxic subjects of two independent multi-
centric SCA3 cohorts and in a SCA3 knock-in mouse model. Ataxic
SCA3 subjects showed increased levels of both NfL and pNfH. In
preataxic subjects, NfL levels increased with proximity to the indi-
vidual expected onset of ataxia, with significant NfL elevations
already 7.5 years before onset. Cross-sectional NfL levels corre-
lated with both disease severity and longitudinal disease progres-
sion. Blood NfL and pNfH increases in human SCA3 were each
paralleled by similar changes in SCA3 knock-in mice, here also
starting already at the presymptomatic stage, closely following
ataxin-3 aggregation and preceding Purkinje cell loss in the brain.
Blood neurofilaments, particularly NfL, might thus provide easily
accessible, cross-species validated biomarkers in both ataxic and
preataxic SCA3, associated with earliest neuropathological
changes, and serve as progression, proximity-to-onset and, poten-
tially, treatment-response markers in both human and preclinical
SCA3 trials.
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Introduction
Spinocerebellar ataxia type 3 (SCA3), also known as Machado–
Joseph disease, is the most common dominantly inherited form of
degenerative ataxia, caused by an expanded CAG repeat in the
ATXN3 gene and marked by irreversible decline in motor function
already in mid-life (Costa Mdo & Paulson, 2012; Rub et al, 2013).
Advances in the understanding of the toxic gain-of-function mecha-
nisms underlying SCA3 neurodegeneration have opened a window
for targeted molecular therapies (Paulson et al, 2017; Ramani et al,
2017). Particularly, interventions with antisense oligonucleotides
(ASOs) targeting mutated ATXN3 show promising results in mitigat-
ing the molecular, pathological and behavioural disease-associated
changes in a SCA3 mouse model (McLoughlin et al, 2018). ASO
treatments might allow preventing the neurodegenerative process
even before the occurrence of clinical symptoms (Finkel et al, 2017;
Winter et al, 2019). However, to pave the way for upcoming trials of
these promising therapies, easily accessible, objective and sensitive
outcome parameters are urgently needed to track disease progression
in both the preataxic and ataxic stage of SCA3 disease. Such parame-
ters require validation in large human SCA3 cohorts with standard-
ised phenotyping and in SCA3 mouse models, as mouse models
allow comprehensive neuropathological validation and preclinical
treatment trials, even already during the presymptomatic stage.
In this cross-species biomarker study, we propose serum concen-
trations of neurofilament light (NfL) and phosphorylated neurofila-
ment heavy (pNfH) as easily accessible, objective and sensitive
blood biomarkers of disease severity in SCA3. Neurofilaments (Nfs)
are neuron-specific cytoskeletal proteins, with constant low-amount
release from neurons in an age-related manner (Disanto et al, 2017;
Gaetani et al, 2019; Khalil et al, 2020) and rapid increase in
response to axonal damage irrespective of the underlying cause (e.g.
traumatic, vascular, inflammatory, degenerative injury). It is yet
unknown whether Nf elevations relate to passive release from
damaged axons and/or upregulated protein production and secre-
tion reflecting attempted axonal regeneration (Paterson et al, 2019).
With novel ultra-sensitive single-molecule array (Simoa) assays, Nfs
are now reliably quantifiable in peripheral blood (Wilke et al, 2016;
Khalil et al, 2018). In fact, while the correlation between Nf levels
in the extracellular compartment of the brain and the cerebrospinal
fluid (CSF) is yet unknown, a close correlation between Nf levels in
the CSF and the peripheral blood has been established for several
neurodegenerative diseases (Bacioglu et al, 2016; Wilke et al, 2016,
2019; Khalil et al, 2018; Gaetani et al, 2019), including also SCA3
(Li et al, 2019). Hereby, Nf levels in blood are roughly 2.5% of the
levels in the CSF (Disanto et al, 2017).
Our previous work in a mixed cohort of repeat-expansion
spinocerebellar ataxias (SCAs) indicated that blood concentrations
of NfL in multisystemic repeat SCAs are increased at the ataxic
disease stage (Wilke et al, 2018), and this also been reported specifi-
cally for SCA3 (Li et al, 2019). However, all these previous studies
were confined to single-centre, single-assay and human-only assess-
ments without any neuropathology associations, as well as to cross-
sectional data. Moreover, they were all restricted to NfL only, while
pNfH might also allow capturing neuronal disintegration and partic-
ularly axonal damage in neurodegenerative disease, possibly captur-
ing differential features of the neurodegenerative process compared
to NfL (Khalil et al, 2018; Wilke et al, 2019).
We here hypothesised that both serum Nfs might serve as blood
biomarkers of disease severity in both human SCA3 and mouse
models, expecting increased concentrations at both the ataxic and
preataxic stage, with increases in preataxic subjects occurring partic-
ularly in proximity to the onset of ataxia. We measured serum
concentrations of both Nfs in cross-sectional samples of ataxic and
preataxic SCA3 subjects and controls in two independent multicen-
tric cohorts, using two independent ultra-sensitive single-molecule
array (Simoa) approaches for each of both Nfs, and correlated Nf
levels with measures of disease severity. We expected the blood Nf
increases in human SCA3 to be paralleled by blood Nf increases in
SCA3 animal models, also starting already in the presymptomatic
stage and at the earliest stages of SCA3 neurodegeneration. We
therefore assessed plasma NfL and pNfH also in a SCA3 knock-in
mouse model (preprint: Haas et al, 2020; Martier et al, 2019) across
presymptomatic and symptomatic disease stages, correlating plasma
concentrations of both Nfs with the temporal course of phenotypic
and neuropathological disease features, including brain ataxin-3
protein levels and aggregation.
Results
Serum NfL levels are increased at the ataxic stage of SCA3
In cohort #1 (Fig 1A), serum concentrations of NfL were signifi-
cantly higher in ataxic SCA3 subjects (34.8 pg/ml (28.3–47.0),
median and IQR) than in controls (8.6 pg/ml [5.7–11.7]; U = 151,
z = 10.1, P < 0.001, r = 0.82). In cohort #2 (Fig 1B), NfL levels were
also significantly higher in ataxic SCA3 subjects (85.5 pg/ml [70.2–
100.2]) than in controls (19.4 pg/ml [15.1–25.4]; U = 16, z = 6.98,
P < 0.001, r = 0.81). This confirmed the NfL increase in a second,
independent cohort with an independent immunoassay. NfL levels
differentiated between ataxic SCA3 subjects and controls with high
accuracy (cohort #1: AUC = 0.97 (0.95–1.00), P < 0.001, optimal
cut-off: 20.0 pg/ml, 98.7% sensitivity, 92.2% specificity; cohort #2:
AUC = 0.99 (0.97–1.00), P < 0.001, optimal cut-off: 50.9 pg/ml,
92.6% sensitivity, 100% specificity). If corrected for age, the NfL
increase in ataxic SCA3 subjects remained highly significant in both
cohort #1 (F(1,147) = 406.54, P < 0.001; based on a linear model
with the factors group, age and their interaction, R2 = 0.82; Fig 1C)
and cohort #2 (F(1,70) = 169.49, P < 0.001, R2 = 0.79; Fig 1D).
Serum NfL levels are increased at the preataxic stage of SCA3
In cohort #1 (Fig 1A), NfL levels of preataxic SCA3 subjects
(29.1 pg/ml [15.9–43.7]) were significantly higher than in controls
(U = 72, z = 3.55, P < 0.001, r = 0.39) and did not differ signifi-
cantly from those of ataxic SCA3 subjects (U = 204, z = 1.48,
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Figure 1. Serum NfL and pNfH concentrations in the preataxic and ataxic stage of SCA3.
A–D Serum NfL concentrations of preataxic (green) and ataxic (red) SCA3 subjects and controls (blue) were measured in two independent cohorts, each with a different
Simoa approach: cohort #1, recruited by the ESMI consortium (A, C), and cohort #2, recruited by the EuroSCA/RiSCA consortium (B, D). Boxes show the ranges
between lower and upper quartiles, the central bands show the medians, and the whiskers show data within 1.5∙IQR of the median, with dots representing
outliers. Groups were compared with Mann–Whitney U-tests (***P < 0.001, **P < 0.01, ns P ≥ 0.05, two-tailed, Bonferroni-corrected; see Appendix Table S3 for
detailed statistics). In the scatter plots, the individual NfL values were plotted as a function of subjects’ age. The dashed grey lines visualise the optimal cut-offs for
differentiating ataxic SCA3 subjects from controls in each cohort (cohort #1: 20.0 pg/ml, 98.7% sensitivity, 92.2% specificity; cohort #2: 50.9 pg/ml, 92.6% sensitivity,
100% specificity; cut-offs were derived by maximising Youden’s index irrespective of age). Note the logarithmic scale of the y-axes.
E, F Serum pNfH levels of preataxic and ataxic SCA3 subjects and controls were also measured in both cohorts, each with a different Simoa approach (two-tailed
Mann–Whitney U-tests, Bonferroni-corrected; see Appendix Table S3 for detailed statistics).
Source data are available online for this figure.
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P = 0.143, r = 0.16, Bonferroni-corrected for multiple comparisons,
respectively). In cohort #2 (Fig 1B), NfL levels of preataxic SCA3
subjects (47.3 pg/ml [25.5–78.0]) were also significantly increased
(U = 88, z = 4.18, P < 0.001, r = 0.53), yet significantly lower than
in ataxic SCA3 subjects (U = 74, z = 3.16, P = 0.001, r = 0.49,
Bonferroni-corrected). Within preataxic subjects, 75% (cohort #1)
and 43% (cohort #2) of NfL levels were above the optimal cut-off
separating ataxic subjects from controls. The NfL increase in prea-
taxic SCA3 subjects remained highly significant if corrected for age,
both in cohort #1 (F(1,81) = 99.27, P < 0.001; based on a linear
model with the factors group, age and their interaction, R2 = 0.68,
Fig 1C) and cohort #2 (F(1,58) = 59.82, P < 0.001, R2 = 0.56,
Fig 1D).
Serum NfL levels reflect disease severity
Neurofilament light levels of ataxic SCA3 subjects significantly
correlated with disease severity (r = 0.43, P < 0.001), as captured
by the SARA score (Fig 2A). The association between NfL and
disease severity remained highly significant if corrected for age
(r = 0.41, P < 0.001), disease duration (r = 0.41, P < 0.001) and
CAG repeat length (r = 0.47, P < 0.001) as possible confounders, as
assessed by partial correlations.
Serum NfL levels may reflect longitudinal disease progression
In a subset of ataxic SCA3 subjects (n = 35, all from cohort #2),
prospective longitudinal SARA scores were available to estimate
intraindividual disease progression, as quantified by the annual
change of the SARA score. Subjects’ cross-sectional NfL levels
significantly correlated with the annual change of the SARA score
(r = 0.34, P = 0.045), suggesting that serum NfL may also reflect
longitudinal disease progression. This positive association was con-
firmed with a similar effect size (r = 0.29) also when adjusting for
baseline SARA score, showing a statistical trend in this relatively
small subcohort (P = 0.100, 2-sided test). Accordingly, subjects with
high disease progression (annual SARA score increase ≥ 0.71
points/year, n = 18, subset defined by median split) had signifi-
cantly higher serum levels of NfL than subjects with low disease
progression (n = 17; P = 0.018, r = 0.40; Fig 2B).
Association of NfL levels with repeat length and age
We analysed the association of NfL levels with age and CAG repeat
length in SCA3 mutation carriers with a linear model, using the
pooled data of both preataxic and ataxic subjects. The highly signifi-
cant predictors of the NfL level were age (F(1,113) = 40.54,
P < 0.001), its square (F(1,113) = 7.91, P = 0.006) and repeat length
(F(1,113) = 22.01, P < 0.001; total explained variance: R2 = 0.37;
Fig 2C). The model demonstrated that, for a given age, each
increase in the CAG repeat count was associated with higher NfL
levels. For a given CAG repeat count, the NfL level increased with
age, with the steepness of the slope declining with increasing age.
Thus, the NfL increase in SCA3 reached a plateau in older age. The
sustained increase of NfL levels through the ataxic stage was
reflected by the absence of correlation of NfL levels with disease
duration (Fig EV1). In controls, the relation between log-trans-
formed NfL levels and age was linear, indicating that any analyses
comparing NfL levels between carriers and controls would need to
consider the physiological NfL age-related increase in controls.
NfL levels increase with proximity to the estimated onset, with
significant increases 7.5 years before ataxia onset
Neurofilament light levels of preataxic subjects increased signifi-
cantly with proximity to the individually predicted onset of ataxia,
as revealed by a linear regression using the pooled data of both
cohorts (F(1,21) = 39.68, P < 0.001, R2 = 0.64; slope: 2.89 [1.94–
3.85], P < 0.001; Fig 3A). To compare preataxic SCA3 subjects with
controls at the same age, we expressed the measured NfL level of
SCA3 subjects as NfL z-score in relation to the age-dependent NfL
distribution in controls (Fig 3B), and analysed the NfL z-score as a
function of the time to the estimated onset of ataxia (Fig 3C). The
NfL z-score significantly increased with preataxic subjects approach-
ing the expected onset of ataxia (F(1,21) = 30.78, P < 0.001,
R2 = 0.58; slope: 0.32 [0.20–0.44], P < 0.001; Fig 3C), without over-
lap of the 95% confidence interval of controls (i.e. if z-score > 1.96)
already 7.5 years before the expected onset (Fig 3C).
Using serum NfL to predict time to estimated onset of ataxia
The estimated time to onset might be predicted from individual NfL
measurements (for z-scores in the range of 1–5) using the regression
depicted in Fig 3C. Moreover, the NfL z-score might allow delineat-
ing a preconversion stage, i.e. stratifying individual preataxic carri-
ers close to expected symptom onset. The NfL z-score differentiated
subjects at the late preataxic stage (i.e. carriers within 10 years of
expected onset) from subjects at the early preataxic stage (i.e. more
than 10 years before the expected onset) with high accuracy
(AUC = 0.89 [0.76–1.00] [95% CI], P = 0.002). Specifically, a cut-off
for the NfL z-score at 3.2 differentiated early from late preataxic
subjects with 85% sensitivity and 90% specificity.
Increased phosphorylated neurofilament heavy (pNfH) levels in
the ataxic disease stage of SCA3
In cohort #1 (Fig 1E), SCA3 subjects at the ataxic stage had signifi-
cantly higher serum pNfH concentrations (110.2 pg/ml [42.9–
277.9]) than controls (22.8 pg/ml [13.9–59.1]; U = 1,064, z = 6.72,
P < 0.001, r = 0.55, Bonferroni-corrected), while pNfH concentra-
tions in preataxic SCA3 subjects (33.9 pg/ml [18.0–184.8]) were not
significantly increased compared to controls (U = 201, z = 1.61,
P = 0.109, r = 0.17). Likewise, in cohort #2 (Fig 1F), serum pNfH
levels were significantly higher in ataxic SCA3 subjects (23.2 pg/ml
[3.2–71.2]) than in controls (3.2 pg/ml [3.2–10.4]; U = 260,
z = 4.57, P < 0.001, r = 0.53), while pNfH concentrations in prea-
taxic SCA3 subjects (4.5 pg/ml [3.2–34.6]) were not significantly
increased (U = 250, z = 1.63, P = 0.103, r = 0.21). These findings
from two independent cohorts and assays validate pNfH increases
in the ataxic stage of SCA3. Such increases might not necessarily be
observed at the preataxic stage of SCA3. However, in both cohorts,
pNfH levels at the preataxic stage were not significantly lower than
in the ataxic stage of SCA3. While levels of NfL and pNfH were
moderately correlated in controls (cohort #1: ϱ = 0.28, P = 0.013,
cohort #2: ϱ = 0.39, P = 0.006), this correlation was only partially
maintained in SCA3 mutation carriers (cohort #1, ϱ = 0.13,
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Figure 2. Associations of NfL levels with disease severity, disease progression, age and CAG repeat length in SCA3.
A Serum NfL levels of ataxic SCA3 subjects significantly correlated with disease severity, as quantified by the Scale for the Rating and Assessment of Ataxia (SARA) score
(r = 0.43, P < 0.001, Pearson’s correlation, two-tailed test).
B The cross-sectional NfL levels also reflected longitudinal disease progression, as quantified by the annual SARA score change (available for 35 subjects). Boxes show
the ranges between lower and upper quartiles, the central bands show the medians, and the whiskers show data within 1.5∙IQR of the median, with dots
representing outliers. Subjects with high disease progression (annual SARA score increase ≥ 0.71 points/year, n = 18, median split) had significantly higher serum
levels of NfL than subjects with low disease progression (n = 17; P = 0.018, r = 0.40, Mann–Whitney U-test, two-tailed; see Appendix Table S3 for detailed statistics).
C We modelled serum NfL levels (log-transformed) in SCA3 carriers (n = 123) with the predictors age and ATXN3 CAG repeat length, their squares and all possible
interactions (for details, see Results and Materials and Methods). The highly significant predictors (age, its square and repeat length, and the intercept, all P < 0.001,
explained variance: R2 = 0.37) were used to generate the diagram. For a given age, each increase in CAG repeat count was associated with higher NfL concentrations.
The steepness of the slopes declined with increasing age. In controls (black, n = 125), the relation between NfL level (log-transformed) and age was linear.
Source data are available online for this figure.
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Figure 3. Association between serum NfL and time from expected onset in preataxic SCA3.
A Serum NfL levels in preataxic SCA3 subjects (cross-sectional data) were plotted over the time from the individually estimated ataxia onset. NfL levels increased
significantly with proximity to the estimated onset (F(1,21) = 39.68, P < 0.001, R2 = 0.64). For benchmarking the levels of preataxic subjects, the blue dashed line
visualises the optimal cut-off for differentiating ataxic SCA3 subjects from controls in the pooled cohort (20.3 pg/ml, 99.0% sensitivity, 95.2% specificity).
B To determine the time at which NfL levels become significantly increased in the preataxic stage of SCA3, NfL levels of preataxic carriers need to be related to NfL
levels of controls at the same age, as NfL levels physiologically increase with age. For each preataxic subject, the difference between the measured NfL value (green
dot) and the NfL value predicted for control subjects of the same age (solid blue line) was visualised by the length of the vertical green line. Standardisation of this
difference relative to the NfL distribution in controls (95% CI of the data: dashed blue line) yielded the individual NfL z-score, which was plotted over each subject’s
estimated time to onset in the next panel.
C In preataxic SCA3 subjects, NfL z-scores increased significantly (F(1,21) = 30.78, P < 0.001, R2 = 0.58) with subjects approaching the expected age of onset. NfL levels
of preataxic subjects were significantly increased compared to controls (i.e. z-score > 1.96) 7.5 years before the expected onset, indicated by the non-overlapping 95%
confidence intervals of SCA3 subjects (black solid line) and controls (blue dashed line).
Source data are available online for this figure.
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P = 0.240, cohort #2: ϱ = 0.33, P = 0.034), suggesting that pNfH
might reflect a partly different feature/process in SCA3 than NfL.
Intraindividual Nf stability and sample size estimation for
intervention trials using Nf levels as outcome parameter
Short-term longitudinal assessment of Nf levels over 6 weeks
(n = 21) demonstrated high intraindividual stability for both NfL
and pNfH in SCA3, as evidenced by very high intraclass correlation
coefficients (ICCs; NfL: 0.983 [0.960–0.993] [95% CI], pNfH: 0.995
[0.987–0.998]; Fig 4A and B). Sample size estimates for hypothetical
intervention trials using the reduction of Nf levels as outcome
parameter indicate, e.g., that  15 subjects per arm would suffice to
detect therapeutic effects with effect sizes as low as 20% (see Fig 4C
also for visualisation of a range of other possible treatment
effect sizes).
Human neuropathology
Neuropathologic examination of SCA3 subject ID27925 (cohort #2)
with an NfL level of 116 pg/ml (93. percentile within the ataxic
subjects of cohort #2) and a pNfH level of 23.2 pg/ml (52. percen-
tile) at age 48.5 years (i.e. 12 months before death) did not show
major degeneration of corticospinal tract, primary motor cortex and
Purkinje cell layer, but marked degeneration of spinocerebellar
tract, dentate nucleus and brainstem (Appendix Table S1). Similarly,
while only rare polyQ pathology was found in the primary motor
cortex and Purkinje cell layer, frequent polyQ pathology was present
in the dentate nucleus, brainstem, basal ganglia and anterior horn.
These findings, which correspond to and further corroborate previ-
ous SCA3 neuropathology case series (Paulson, 2012; Paulson et al,
2017; Koeppen, 2018), preliminarily indicate that not the corti-
cospinal tract, motor cortex and cerebellar cortex, but rather affec-
tion of the spinocerebellar tract and brainstem, might underlie the
Nf increase in SCA3.
Plasma neurofilament levels in a SCA3 mouse model are
increased in proximity to phenotypic onset
To elucidate the temporal cascade of Nf concentrations in SCA3, we
analysed blood concentrations of Nfs in a 304Q SCA3 knock-in
mouse model with a phenotypic onset at around 8 months of age,
sampling animals at age 2 months (= early presymptomatic),
6 months (= late presymptomatic), 12 months (= early symp-
tomatic) and > 18 months (= late symptomatic disease stage).
While plasma concentrations of NfL were not yet increased at
2 months, they significantly increased already at age 6 months
(P < 0.001) and 12 months (P < 0.001, Bonferroni-corrected) in
heterozygous mutants compared to wild-type animals, with this
effect levelling out in late symptomatic mice at age > 18 months
(Fig 5A). Analogously, plasma concentrations of pNfH were signifi-
cantly increased at 6 months (P < 0.01) and 12 months (P < 0.001)
in heterozygous mutants compared to wild-type animals, but not at
2 months and > 18 months, supporting an increase in Nf blood
concentrations in proximity to the phenotypic onset (Fig 5B).
Exploratory analysis of Nf plasma levels in homozygous mutants
confirmed the temporal cascade observed in heterozygous animals
(Fig EV2). Tissue concentrations of NfL and pNfH in the cerebellum
and frontal lobe did not differ between mutant and wild-type
animals at the presymptomatic and symptomatic disease stage,
preliminarily suggesting that the differences observed in the blood
concentrations might relate not to changes of the amount of Nfs
A B C
Figure 4. Within-subject stability of Nf levels and sample size estimates for clinical trials.
A, B Longitudinal intraindividual stability of NfL (A) and pNfH (B) serum levels over 6 weeks, assessed in both ataxic (red) and preataxic (green) SCA3 and control (blue)
subjects (n = 21). Data of the same individuals are linked by lines. ICC, intraclass correlation coefficient (estimate and 95% CI).
C Sample size estimations were performed for future intervention trials using the reduction of Nf levels towards control levels as outcome measure. The estimated
number of subjects per study arm is plotted over the assumed therapeutic effect for lowering the Nf level in SCA3 subjects to levels observed in healthy controls
(NfL: dashed line, pNfH: dotted line).
Source data are available online for this figure.
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Figure 5. Neurofilament plasma levels and brain tissue levels of soluble and aggregated ataxin-3 in the 304Q SCA3 mouse model.
A, B Plasma concentrations of NfL (A) and pNfH (B) were measured in the 304Q knock-in SCA3 mouse model. Heterozygous animals become symptomatic at
 8 months of age.
C–F Tissue levels of soluble and aggregated mutant ataxin-3 were measured in cerebellum (C, E) and frontal lobe (D, F). Exploratory analyses in homozygous animals
confirmed the ataxin-3 increases observed in heterozygous animals (Fig EV4).
Data information: Heterozygous and wild-type animals were compared by two-tailed unpaired t-tests, adjusted for unequal variances (***P < 0.001, **P < 0.01,
*P < 0.05, ns P ≥ 0.05, Bonferroni-corrected; see Appendix Table S3 for detailed statistics). Dots show individual measurements, bars indicate mean  SD (calculated for
log-transformed values).
Source data are available online for this figure.
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within the brain tissue, but rather to the release of Nfs from the
brain tissue with neurodegenerative decay (Fig EV3). Brain Nf
concentrations were hereby higher in the cerebellum than in the
frontal lobe, suggesting higher share of axonal tissue in the cerebel-
lum, and thus adding further support that axonal damage markers
—such as Nfs—might be promising markers for degenerative cere-
bellar disease.
Both NfL and pNfH increases in SCA3 relative to wild-type mice
started earlier (age: 6 months, both males and females; Fig EV2)
than the weight phenotype (age: 7 months, males; age: 12 months,
females; Appendix Fig S1) and the motor phenotype (age:
18 months, both males and females; Appendix Fig S2), highlighting
their value as proximity blood biomarkers for the preconversion
stage also in mice. While Nf levels increased later than both aggre-
gated and soluble cerebellar mutant ataxin-3 (age: 2 months; Fig 5C
and E), ataxin-3 levels did not change throughout the disease course
and in particular not with proximity to conversion (Fig 5C and E;
for ataxin-3 tissue levels in homozygous mice, see Fig EV4). This
indicates that, in contrast to Nfs, ataxin-3 levels might serve not as
preconversion markers, but possibly rather as target-engagement
markers. Taken together, our biomarkers and phenotype parameters
allow mapping a preliminary multimodal chart of disease evolution
in the 304Q SCA3 mouse model from the early preataxic to the late
ataxic stages of SCA3 disease (Fig 6).
Temporal sequence of associated murine neuropathology
To elucidate the brain pathology changes temporally associated with
the onset of the plasma Nf increase, we investigated the temporal
sequence of neuropathology changes in SCA3 mice. Ataxin-3 aggre-
gation started at months 2–3 and was clearly present at month 6 in
regions typically affected by SCA3, particularly the cerebellum, pons
and frontal cortex (Fig 7A), thus partly preceding, partly paralleling
the onset of the plasma Nf increase. Purkinje cell (PC) loss started
at months 2–3, but did not become significant before 12 months of
age (Fig 7B, Appendix Fig S3), thus partly paralleling, but largely
succeeding the onset of the Nf increase. Interestingly, at the onset of
the Nf increase in blood (i.e. month 6), structural changes in PCs
were microscopically more prominent than absolute PC loss
(Appendix Fig S3), which might suggest that incipient structural
alteration, and not only PC cell death, might contribute to Nf release
in SCA3. These PC alterations were accompanied by structural
Figure 6. Biomarker cascade of NfL, pNfH, cerebellar aggregated and soluble ataxin-3 and phenotype in 304Q knock-in SCA3 mice.
The figure shows the degree to which each variable differs between heterozygous SCA3 mice and wild-type controls for a given age. For each variable, we quantified the
deviation of heterozygous mice from controls of the same age by calculating the effect size r of the group comparison (independent t-tests). An effect size of 0 indicates that
the value in heterozygousmice is not different from controls, while an effect size of 1 would indicate strong abnormality. Note that the drop in the effect size of Nf levels from
12 to 18 months thus does not imply a putative reduction of Nf levels, but rather the loss of the effect in mutants relative to controls, as controls show strong age-related Nf
increases at 18 months of age. Negative effect size values were set to 0.
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A
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Figure 7. Ataxin-3 immunohistochemistry and histological assessment of Purkinje cells in the 304Q SCA3 mouse model.
A We assessed samples of cerebellar cortex, deep cerebellar nuclei, frontal cortex, pons and pyramidal tract by immunohistochemistry with ataxin-3 staining,
comparing heterozygous 304Q SCA3 mice at 2, 6, 12 and 18 months of age with wild-type animals at 18 months.
B We histologically assessed the number and integrity of Purkinje cells in the cerebellar cortex by NfL, pNfH, Nissl and calbindin staining, comparing heterozygous
304Q SCA3 mice at 2, 6, 12 and 18 months of age with wild-type animals.
Data information: GL, granular layer; ML, molecular layer, PC, Purkinje cells, scale bars: 20 lm.
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disturbance of the NfL and pNfH network in the cerebellar cortex
(Fig 7B). No marked overall atrophy of the deep cerebellar nuclei,
pons, frontal cortex and pyramidal tract was observed (Fig EV5,
Appendix Fig S4). Taken together, this indicates that Nf increases in
blood occur with strong effect sizes already at the earliest stages of
SCA3 disease, shortly following onset of ataxin-3 aggregation and
coinciding with PC structural alterations even prior to PC loss, and
are not secondary to marked overall atrophy of pertinent SCA3 brain
regions.
Discussion
To pave the way for upcoming treatment trials, easily accessible
surrogate biomarkers are highly warranted in SCA3 for both human
and preclinical trials. In this comprehensive cross-species study—
leveraging two independent large multicentric human cohorts and a
knock-in mouse model, each covering both presymptomatic and
symptomatic SCA3 disease stages and including both blood and
neuropathology assessments—we demonstrate that (i) NfL levels
are increased not only at the ataxic, but also in the preataxic stage
of SCA3 in both humans and mice, increasing with repeat length
and age and with proximity to expected disease onset in humans;
that (ii) pNfH levels are increased at the ataxic stage of human
SCA3 and at both the preataxic and ataxic stage of murine SCA3;
and that (iii) these peripheral blood changes in both NfL and pNfH
closely follow ataxin-3 aggregations and coincide with early PC
structural alterations in the brain even prior to marked PC cell loss.
The observed increases in human NfL and pNfH serum levels in
SCA3 seem to present a highly robust finding as they were each con-
firmed in two independent cohorts with two different Simoa assays.
NfL levels differentiated SCA3 subjects from controls with high
accuracy, with effect sizes comparable to state-of-the-art magnetic
resonance spectroscopy methods (Adanyeguh et al, 2015; Joers
et al, 2018). These Nf increases in SCA3 might not be primarily of
help as a diagnostic biomarker, as Nfs are increased in many
neurodegenerative and non-neurodegenerative conditions, including
several multisystemic ataxias (Wilke et al, 2018). This is, however,
not primarily needed for SCA3, as assessment of the ATXN3 repeat
expansion or the mutant protein meets this biomarker purpose.
Rather, for preparing upcoming treatment trials, the biomarker
value of NfL levels might lie in their potential as disease severity,
progression and stratification biomarker, or—in terms of the
Biomarker Qualification Program of the Food and Drug Administra-
tion (FDA)—in their potential as monitoring, prognostic, response
and/or safety biomarker for SCA3 drug development. We here
demonstrate that NfL levels indeed correlate not only with cross-
sectional disease severity, but also with the longitudinal annual
change of the SARA score within individuals. These significant asso-
ciations, though moderate in effect size, indicate that NfL blood
levels might serve as easily accessible fluid biomarkers of disease
severity in SCA3. Given that NfL levels distinguish fast vs slow
disease progressors, they might also aid as stratification markers of
SCA3 patients in upcoming treatment trials according to categories
of disease progression. As NfL levels thus reflect disease severity
and disease progression rates, but not clinical disease duration
(Fig EV1), they seem to capture the functional stage and ongoing
neuronal decay of SCA3 disease, rather than the mere calendrical
estimate of duration of the disease. Increased NfL levels therefore
might be related to spinocerebellar tract (and possibly brainstem)
degeneration in SCA3, rather than, e.g., corticospinal tract degenera-
tion (as, e.g., in ALS (Menke et al, 2015; Skillback et al, 2014)),
as suggested by our human neuropathological findings. The
neuropathological association observed in our study corroborates,
but at the same time specifies previous relatively broad volumetric
MRI findings suggesting an association of NfL levels with cerebellar
volumes and brainstem volumes (Li et al, 2019). Our single-subject
neuropathology finding, however, requires validation in larger SCA3
cohorts with combined neuropathology and Nf assessment.
Neurofilament light levels appear to be strongly influenced, inter
alia, by CAG repeat length and age, as both factors were found to
present independent significant predictors of individual NfL levels.
For a given age, each increase in the CAG repeat count was associ-
ated with higher NfL levels. This association between NfL levels
and CAG repeat length suggests a dose–response relationship for
SCA3 neurodegeneration and, together with analogous findings in
Huntington’s disease (Byrne et al, 2017), more generally for polyg-
lutamine disorders. For a given CAG repeat length, NfL levels
increased with age, with the steepness of the slope decreasing with
increasing age; i.e., the NfL increase in SCA3 reached a plateau in
old age.
In both human cohorts, NfL levels were already increased at the
preataxic stage of the disease, hereby, the individual estimated time
to onset might even be predicted from individual NfL levels. The
NfL increase preceded the conversion to the ataxic stage by
7.5 years, with levels further increasing with proximity to the indi-
vidually predicted onset of ataxia. NfL levels might thus allow to
capture the onset of degenerative neuronal loss and the subclinical
progression in the preataxic stage, possibly even on a single-subject
level. They might moreover aid to stratify a window of opportunity
in which future disease-modifying therapies might be most effective.
If future longitudinal assessments of converters confirm this NfL
increase with proximity to ataxia onset (i.e. NfL as proximity/
preconversion stratification biomarker), NfL might aid the selection
of preataxic candidate subjects for therapeutic intervention, as inva-
sive treatments (like ASOs) should likely be applied neither unnec-
essarily early nor too late in preataxic SCA3 subjects.
Short-term longitudinal assessment of Nf levels demonstrated
both NfL and pNfH blood levels to be highly stable within subjects,
suggesting that intraindividual biological variation is likely a mini-
mal source of noise in observation and intervention trials using Nf
blood levels as outcome measure. Our sample size estimations for
future treatment trials aiming to lower Nf blood levels in SCA3
showed that already  15 subjects per arm would suffice to detect
therapeutic effects, even for therapeutic effect sizes as low as 20%.
This number is considerably below the cohort sizes which would
likely be required for clinical endpoints, e.g. SARA score (Jacobi
et al, 2015). Nf levels might thus provide a means for reducing trial
sample size similar to or even more than the most change-sensitive
MRI parameters (Reetz et al, 2013; Adanyeguh et al, 2018).
Serum levels of pNfH in both cohorts were increased at the ataxic
stage of human SCA3, but—unlike NfL levels—not the preataxic
stage. Given the higher sensitivity of NfL to capture changes already
at the preataxic stage of human SCA3, our findings prioritise the use
of NfL over pNfH in future SCA3 treatment trials. However, given
their clear increase and high intraindividual stability, both markers
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might still be further explored as combined fluid biomarkers in
future longitudinal SCA3 trials, as they might show differential
responses and dynamics to disease-modifying treatments or capture
different features underlying multifaceted neurodegeneration, as
suggested for other neurodegenerative diseases (Poesen & Van
Damme, 2018; De Vivo et al, 2019; Winter et al, 2019).
Increases of NfL and pNfH blood levels in our two human SCA3
cohorts were paralleled by corresponding increases in our SCA3
mouse model, validating their value as neuronal damage biomarker
in SCA3 across species. In mice, not only NfL, but also pNfH,
showed increases before the onset of the phenotype, namely at age
6 months, thus validating the preataxic increase of Nf blood levels
observed in human SCA3. Moreover, again mirroring the findings
from human SCA3, these increases were sustained in SCA3 mice
during the further disease course (i.e. at age 12 months), before the
effects were then levelled out by the age-related increases in Nfs in
elderly wild-type mice (i.e. at age > 18 months). Taking together
our human and murine results, the temporal dynamics of Nfs in
SCA3 might hence be non-linear, with a boost of Nfs (in particular
NfL) in proximity to phenotype conversion, and stabilisation of
increased levels afterwards. Similar models of Nf dynamics have
been proposed for other neurodegenerative diseases such as amyo-
trophic lateral sclerosis (ALS) (Weydt et al, 2016) or frontotemporal
dementia (FTD) (van der Ende et al, 2019). Hence, Nf levels (in
particular NfL) might be particularly sensitive to neuronal decay in
the early disease stage of SCA3, where biomarkers for tracking
disease intensity would be most needed given the absence of
change-sensitive clinical parameters.
The SCA3 mouse model also allowed us to assess the associated
histological and immunohistochemical change at the time of the Nf
increase. The peripheral blood Nf increases occur already at the
earliest stages of SCA3 disease, shortly following onset of SCA3
brain hallmarks (ataxin-3 aggregation) and coinciding with incipi-
ent SCA3 neurodegeneration (PC structural alterations) even prior
to PC cell loss. This finding again highlights the power of
peripheral Nfs to coincide with early central nervous SCA3
neurodegenerative processes.
Going beyond mere immunohistochemistry and histology, the
mouse model also allowed us to more specifically relate the
biomarker cascade of peripheral Nf levels to central ataxin-3 levels.
Both soluble and aggregated mutant ataxin-3 increases in the cere-
bellum were detectable earlier than Nf increases (Fig 5C and E), in
line with the notion that they occur further upstream in SCA3 patho-
genesis compared to the axonal damage reflected by Nf levels. Inter-
estingly, in the frontal lobe aggregated mutant ataxin-3 seemed to
increase later than blood Nf levels (Fig 5D and F), again corroborat-
ing the notion that the Nf increase in blood does not lag behind
largely after ataxin-3 aggregation in some brain areas. In contrast to
Nfs, however, ataxin-3 levels did not rise further during the late
presymptomatic and early symptomatic stage in SCA3 mice. This
indicates that while mutant ataxin-3 levels might serve as target-
engagement biomarker, they are of limited value as biomarker of
disease severity or progression (in contrast to Nfs), at least in this
SCA3 mouse model. Nfs and mutant ataxin-3 might thus be used as
complementary composite biomarkers with differential utility in
future preclinical SCA3 mouse treatment trials.
Taken together, our study thus not only confirms, but rather
largely extends recent studies indicating an NfL increase in human
SCA3 (Wilke et al, 2018; Li et al, 2019), as these studies were non-
multicentric, single-assay, human- and NfL-only studies, lacking the
comparative assessment of several molecular biomarkers, the rela-
tive biomarker cascade mapping and any neuropathology associa-
tions. Specifically, our study extends previous research in multiple
ways, namely by: demonstrating the association of NfL levels with
longitudinal disease progression; providing short-term longitudinal
Nf measurements as the basis for sample size estimations for future
treatment trials; cross-validating two different Nf assays; delineating
in preataxic SCA3 the increase of NfL levels with temporal proximity
to the expected disease onset, thus allowing to define a preconver-
sion stage; revealing NfL and pNfH increases also in murine SCA3,
thus preparing the translational path for Nfs as outcome measures
in preclinical studies; relating the Nf changes to other molecular
biomarkers (such as ataxin-3), thus placing Nfs into a larger
biomarker cascade landscape; and relating peripheral Nf changes to
central human and murine SCA3 brain pathology, thus providing
first preliminary insights into the early SCA3 brain degeneration
processes associated with the blood Nf increase.
Our study has several limitations. First, longitudinal assessment of
Nf levels covering not only a short-term interval (as in our study),
but also longer intervals is warranted to confirm our cross-sectional
Nf findings. Such long-term intraindividual temporal dynamics of Nfs
might be even more sensitive to early stages of degeneration and
better suited to capture individual disease progression, as indicated
by longitudinal Nf studies of genetic FTD and Alzheimer’s disease
(van der Ende et al, 2019; Preische et al, 2019). Second, association
of Nf levels with larger neuropathological and/or MRI datasets is
warranted to determine the regions of the central nervous system,
which mainly drive the Nf increases, and to disentangle the differen-
tial dynamics and systems contributing to NfL vs pNfH increases.
Yet, our study has identified the first set of fluid biomarker candidates
for both human and preclinical treatment trials in SCA3.
Materials and Methods
Human cohorts
Serum Nf concentrations were assessed in cross-sectional samples
from two independent multicentric international SCA3 cohorts.
Cohort #1 was recruited by the ESMI consortium (European
Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative,
recruitment period: 2016–2018), comprising 83 SCA3 subjects and 77
healthy controls. Cohort #2 comprised 41 SCA3 subjects and 48
healthy controls from the EuroSCA (European integrated project on
spinocerebellar ataxias) and RiSCA (prospective study of individuals
at risk for spinocerebellar ataxia) cohorts (recruitment period: 2008–
2016, clinicaltrials.gov: NCT01037777) (Jacobi et al, 2013, 2015). The
recruitment of these studies included subjects with genetically con-
firmed SCA3 (ATXN3 repeat length ≥ 53; for determination of CAG
repeat length, see Appendix Supplementary Methods), their first-
degree relatives (i.e. siblings and children) and unrelated neurologi-
cally healthy controls. Based on their score on the Scale for the
Assessment and Rating of Ataxia (SARA) (Schmitz-Hubsch et al,
2006), SCA3 mutation carriers were classified as either ataxic (SARA
score ≥ 3, cohort #1: 75 subjects, cohort #2: 27 subjects) or preataxic
(SARA score < 3, cohort #1: 8 subjects, cohort #2: 14 subjects).
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Controls comprised mutation-negative first-degree relatives of SCA3
carriers and unrelated healthy individuals, all without symptoms or
signs of neurodegenerative disease. Sample size calculation was
based on a piloting study indicating that 15 ataxic SCA3 subjects and
15 controls would suffice to detect significant differences of NfL
serum levels between groups (assuming a = 0.01, b = 0.01, equal
group size, use of two-tailed non-parametric test) (Wilke et al, 2018).
However, we here included all available SCA3 subjects in each cohort
to assess associations of Nf levels with clinical and genetic variables.
For 35 SCA3 subjects in cohort #2, longitudinal SARA scores were
available. To assess intraindividual analyte stability, we additionally
collected short-term longitudinal blood samples in a subset of
subjects from cohort #2 who were available at a second visit 6 weeks
after the baseline visit (n = 21 subjects: seven ataxic, six preataxic
and eight control subjects; sampling interval: 42 days [34–49],
median [IQR]). Demographic, clinical and genetic characteristics of
both cohorts are detailed in Table 1. All subjects provided written
informed consent prior to participation according to the Declaration
of Helsinki. The study was approved by the local ethics committees
of the University of Tübingen and the other study sites.
Genotyping of SCA3 subjects
The repeat length of the expanded and normal alleles was deter-
mined by PCR-based fragment length analysis from 100 to 250 ng
genomic DNA (CEQ8000 capillary sequencer, Beckman Coulter).
CAG repeat length was determined in a centralised manner for
cohort #1.
Human serum and neuropathology
Blood samples were centrifuged (4,000 g, 10 min, room tempera-
ture). Serum was frozen at 80°C within 60 min after collection,
shipped and analysed without any previous thaw–freeze cycle.
Post-mortem brain and spinal cord tissue of the SCA3 subject
ID27925 was assessed for degeneration and polyQ aggregates
(Appendix Table S1).
Mouse model, murine plasma and neuropathology
We used the 304Q SCA3 knock-in mouse model containing a 304
trinucleotide repeat expansion in the murine ATXN3 homolog,
which was generated on the background of C5BL/6N mice (Charles
River) by zinc finger technology (Carbery et al, 2010), as described
in detail elsewhere (preprint: Haas et al, 2020; Martier et al, 2019).
In short, this method resulted in a double-strand break within the
murine (CAACAGCAG)2 region and the introduction of a specific
expansion of the CAACAGCAG region accomplished by homologous
recombination using a donor vector with (CAACAGCAG)48 repeats,
flanked by 800 bp up- and downstream of ATXN3 (for a more
detailed description of the mouse model, see preprint: Haas et al
(2020)). More repeats than contained in the donor vector were
introduced, resulting in the expression of 304 glutamines in the
ataxin-3 protein under control of all endogenous regulatory
elements. The length of the expansion was chosen to trigger a more
pronounced behavioural phenotype than observed in other knock-in
SCA3 models, where the polyQ expansion length is in the range of
SCA3 patients, but which display only mild or no phenotypes
(Ramani et al, 2015, 2017; Switonski et al, 2015). We used an inter-
rupted CAG repeat (interruptions of the CAG repeat by CAA, i.e.
(CAGCAGCAA)n) as (i) this allowed to ensure meiotic stability of
the repeat length across generations (i.e. to keep the repeat length
stable) (Frontali et al, 1999), and as (ii) an interrupted repeat is also
found in the murine ataxin-3 locus. We genotyped animals
(n = 147) by PCR, using DNA extracted from ear biopsies with the
High Pure PCR Template Preparation Kit (Roche).
Table 1. Demographic, clinical and genetic characteristics of the human SCA3 cohorts.
Cohort #1 (ESMI) Ataxic SCA3 Preataxic SCA3 Controls
Sample size (female) 75 (56.0%) 8 (87.5%) 77 (41.6%)
Age (years) 52.3 (45.7–61.0) 33.7 (30.1–36.9) 43.5 (31.4–58.9)
Reported age of onset (years) 40.0 (33.0–46.5) NA NA
Disease duration based on reported age of onset (years) 11.0 (7.2–15.1) NA NA
SARA score 13.0 (10.0–21.5) 1.0 (0.5–2.0) NA
Repeat count (long allele) 70 (67–71) 70 (67–71) NA
Predicted time to onset (years) NA 9.1 (7.7–13.4) NA
Cohort #2 (EuroSCA/RiSCA) Ataxic SCA3 Preataxic SCA3 Controls
Sample size (female) 27 (48.1%) 14 (42.9%) 48 (52.1%)
Age (years) 50.9 (46.3–55.0) 36.7 (28.2–45.5) 40.7 (31.2–50.0)
Reported age of onset (years) 40.0 (35.3–46.0) NA NA
Disease duration based on reported age of onset (years) 10.9 (6.1–16.9) NA NA
SARA score 11.5 (6.5–15.0) 1.0 (0.5–1.5) NA
Repeat count (long allele) 69 (66–70) 69 (65–70) NA
Predicted time to onset (years) NA 9.8 (8.8–14.3) NA
Data are reported as median and interquartile range.
NA, not applicable.
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The study comprised 147 animals (56 heterozygous, 37 homozy-
gous and 54 wild-type) with balanced sex within the genotypic
groups. For the primary analysis, we aimed to sample ≥ 10 animals
per genotype (heterozygous/wild-type) and age group (2/6/12/
18 months), based on effect sizes observed in human studies (Wilke
et al, 2018) and in previous murine studies (Bacioglu et al, 2016);
no animals were excluded from the analyses. Within each genotype,
animals were randomly allocated to an age group (2, 6, 12 or
18 months of age). Animals were dissected following CO2 introduc-
tion. Blood was obtained by heart puncture with heparinised
syringes, collected in 1.3 ml lithium heparin tubes and centrifuged
(3,000 g, 20 min, 4°C) to obtain plasma. Samples were then
aliquoted (70 ll) and stored at 80°C until use. Cerebellum and
frontal lobe tissue were homogenised in Precellys CK14 tubes on the
Precellys 24 homogeniser (VWR) at 10% (w/v) in homogenisation
buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, contain-
ing proteinase inhibitor [cOmplete Protease Inhibitor Cocktail,
Roche]). Cerebellar samples were further treated with ultrasonic
waves for better homogenisation. The homogenised brain tissue
was centrifuged at 25,000 g, 4°C, for 60 min. The supernatant was
aliquoted and diluted 1:10,000 in sample diluent. We quantified
tissue levels of soluble mutant ataxin-3 by time-resolved Förster
resonance energy transfer immunoassay (TR-FRET) (Nguyen et al,
2013) and aggregated mutant ataxin-3 by filter retardation assay
(Weber et al, 2017; Weishäupl et al, 2019), as detailed below.
Murine histology and immunohistochemistry
The mice sampled for these analyses were transcardially perfused
with cold PBS and 4% paraformaldehyde (PFA). Brains were post-
fixed in 4% PFA overnight at 4°C before paraffin embedding. Seven-
micrometer sagittal sections were cut with the Leica RM2155 micro-
tome (Leica, Germany). Before staining, sections were rehydrated in
xylene and a graded alcohol series with the Leica Autostainer XL.
For immunohistochemistry, microwave treatment with 10 mM
sodium citrate and 10 mM citric acid for 15 min and threefold wash-
ing with phosphate-buffered saline (PBS) were performed. Endoge-
nous peroxidase was blocked by 1.6% peroxidase (Sigma-Aldrich,
Germany). After washing with PBS, sections were blocked in 5%
normal goat serum (NGS; Vector Laboratories, USA) in PBS supple-
mented with 0.3% Triton X-100 (Carl Roth, Germany) at room
temperature for 45 min. After washing with PBS, sections were
incubated with primary antibodies: mouse anti-ataxin-3 (clone 1H9,
1:500, MerckMillipore, Germany), mouse anti-calbindin (D28-K,
1:1,000, Swant, Switzerland), mouse anti-neurofilament L (NfL,
clone NFL3, 1:500), and mouse anti-neurofilament H and phospho-
rylated anti-neurofilament H (clone SMI31, 1:1,000, both from Biole-
gend, USA), diluted in PBS containing 15% NGS overnight at 4°C in
a humid chamber. After washing with PBS, biotinylated secondary
antibody (goat anti-mouse, 1:200, Vector Laboratories, Burlingame,
USA) was incubated on the sections for 1 h at room temperature.
Afterwards, sections were incubated with avidin–biotin complex
(ABC; Vector Laboratories, USA) for 1 h at room temperature. After
washing, the substrate 3,30-Diaminobenzidin (DAB, Sigma-Aldrich,
Munich, Germany) was added to the sections and the reaction was
stopped in distilled water. After dehydrating, the sections were
mounted with CV Ultra Mounting Media (Leica, Germany). For
cresyl violet (Nissl) staining, rehydrated sections were incubated in
0.1% Cresyl Violet Stain Solution (ab246816, Abcam, UK) for 5 min
at room temperature. Afterwards, sections were shortly rinsed in
distilled water to reduce background noise and dehydrated in alco-
hol and xylene before mounting with CV Ultra Mounting Media.
Imaging of the sections was performed using the Axioplan2 imag-
ing microscope with an AxioCam HR colour digital camera and the
AxioVision SE64 Rel. 4.9 software (Zeiss, Germany). All quan-
tifications of cell number were performed in 2 mice per genotype
and age and 4 different sections (= cerebellar loops) per mouse,
with the examiner being blinded to genotype and age. Size of deep
cerebellar nuclei was quantified from cresyl violet-stained sections
using AxioVision SE64 Rel. 4.9 software. Cell number of pontine
nuclei and frontal cortex was assessed on the basis of cresyl violet
staining of 3 visual fields at 20× magnification using ImageJ (im-
agej.nih.gov). Briefly, colour images were converted to 16-bit grey-
scale and threshold was adjusted to highlight all structures. To
count cells automatically, the function “analyse particles” in ImageJ
was used. Purkinje cells (PCs) were quantified and classified manu-
ally into the categories “altered” (= shrinkage of PC soma), “lost”
(= no visible PC soma) and “intact” based on NfL and Nissl-stained
cerebellar sections.
Phenotypic assessment of mice
Given the strong abnormal weight phenotype of our SCA3 mouse
model, indicating severe underlying disease processes already early
in the disease course, weight was determined longitudinally in all
animals every 2 weeks. Additionally, in an independent cohort of
304Q SCA3 mice (n = 45), evolution of coordination and balance
was assessed by quantitative gait analysis using the Catwalk 8.1 gait
analysis system (Noldus). Animals were tested every 6 months
starting with 6 months of age, 12–15 mice per genotype were anal-
ysed per time point. Each mouse had to complete five runs with a
minimal run duration of 0.5 s and maximum of 10 s. Speed varia-
tion had to be below 60%. Run performance and footprint analysis
were performed with Catwalk X software (Noldus).
The experiments were conducted in accordance with the veteri-
nary office regulations of Baden–Wuerttemberg, Germany (Regier-
ungspräsidium Tübingen: HG3/13, HG2/18), the German Animal
Welfare Act and the guidelines of the Federation of European Labo-
ratory Animal Science Associations, based on European Union legis-
lation (directive 2010/63/EU). Animals were housed under standard
conditions in groups (≤ 5 per cage) and maintained within a 12-h
light–dark cycle. Access to food and water was given ad libitum.
Neurofilament quantification
Neurofilament concentrations were measured in duplicates by ultra-
sensitive single-molecule array (Simoa) technique on the Simoa HD-
1 Analyzer (Quanterix, Lexington, Massachusetts). In cohort #1, we
used the NF-light Advantage Kit for NfL (Kuhle et al, 2016) and the
pNF-heavy Discovery Kit for pNfH quantification (Wilke et al,
2019), according to the manufacturer’s instructions (Quanterix). In
cohort #2, we quantified Nf concentrations using an independent
homebrew NfL-pNfH duplex assay, as detailed below. Given the
minute volumes that suffice for measuring both analytes by the NfL-
pNfH duplex assay (70 ll per sample), we also used this duplex
assay for quantifying Nf concentrations in murine plasma and
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murine brain lysates from cerebellum and frontal lobe. All samples
were measured in duplicates (dilution for serum/plasma: 1:4, for
lysates: 1:2,000). Technicians were blinded to the genotypic and
phenotypic status of the samples. Validation with 47 independent
serum samples (13 SCA3 subjects, 34 controls) confirmed excellent
agreement between the Quanterix and the homebrew NfL assays
(R = 0.99). This allowed transformation of the NfL homebrew
measurements to the scale of the Quanterix measurements by linear
regression (see Appendix Table S2 for assay characteristics and vali-
dation). For pNfH, analogous validation also showed good, yet
lower, agreement between the Quanterix and the homebrew pNfH
assays (R = 0.88).
Homebrew NfL-pNfH duplex Simoa assay
Neurofilament light and pNfH levels in cohort #2 were measured by
an in-house multiplex Simoa assay. For NfL, the monoclonal anti-
body (mAB) 47:3 was used as capture antibody and mAB 2:1 as
detector antibody (UmanDiagnostics, Umeå, Sweden). pNfH was
captured by mouse mAB anti-human pNfH (Iron Horse Diagnostics,
USA) and detected by chicken polyclonal anti-human pNfH antibod-
ies (Iron Horse Diagnostics). Each capture antibody was separately
coupled to dye-encoded paramagnetic beads using a procedure
previously described (Disanto et al, 2017). Bovine-lyophilised NfL
was obtained from UmanDiagnostics and purified pNfH from Iron
Horse. Calibrators ranged for NfL from 0 to 2,000 pg/ml, and for
pNfH from 0 to 400 pg/ml (calibrator diluent: tris base saline [TBS];
0.1% Tween-20; 1% milk powder; 300 lg/ml Heteroblock [Omega
Biologicals Inc., Bozeman, USA]). Batch prepared calibrators were
stored at 80°C. Calibrators (neat) and samples (serum/plasma 1:4
dilution, lysates 1:2,000 dilution; sample diluent: TBS, 0.1% Tween-
20, 1% milk powder, 400 lg/ml Heteroblock [Omega Biologicals])
were measured in duplicates. Reagents were prepared as follows: NfL
and pNfH beads were diluted to 1 × 104 beads/ll each, and detector
antibodies for NfL and pNfH were adjusted to 0.1 and 0.05 lg/ml,
respectively (bead and detector diluent: TBS; 0.1% Tween-20; 1%
milk powder; 300 lg/ml Heteroblock [Omega Biologicals]). Paral-
lelism of the assay for serum, plasma and brain lysates was con-
firmed by serial dilution experiments in native samples.
Quantification of soluble ataxin-3
Soluble mutant ataxin-3 measurements via time-resolved Förster
resonance energy transfer immunoassay (TR-FRET) were performed
using a combination of an anti-ataxin-3 antibody (clone 1H9,
MAB5360, Merck) labelled with Tb (donor) fluorophore and an
anti-polyQ antibody (clone 1C2, MAB1574, Merck) labelled with d2
(acceptor) fluorophore (labelling by Cisbio). Briefly, homogenised
cerebellar and frontal lobe samples for Nf measurements were
diluted in homogenisation buffer (50 mM Tris, 150 mM NaCl,
5 mM EDTA, cOmplete Protease Inhibitor Cocktail) to a final
concentration of 1 lg/ll total protein amount. Next, 5 ll of diluted
sample was incubated with 1 ll of the TR-FRET antibody mix (1 ng
1H9-Tb + 3 ng MW1-d2 in 50 mM NaH2PO4, 400 mM NaF, 0.1%
BSA, 0.05% Tween-20) in a low-volume white ProxiPlate 384 TC
Plus plate (PerkinElmer) at 4°C for 22 h. Signals were detected at
620 nm and 665 nm using an EnVision Multimode Plate Reader
with a TRF-laser unit (PerkinElmer).
Quantification of aggregated ataxin-3
For the filter retardation assay, 12.5 lg of protein homogenate was
diluted in Dulbecco’s phosphate-buffered saline (DPBS; Gibco)
containing 2% sodium dodecyl sulphate (SDS) and 50 mM 1,4-
dithiothreitol (DTT) and heat-denatured for 5 min at 95°C. Samples
were filtered through Amersham Protran Premium 0.45-lm nitrocel-
lulose membranes (GE Healthcare) by using a Minifold II Slot-Blot
System (Schleicher & Schuell). Before loading the samples, the
membrane was equilibrated with DPBS containing 0.1% SDS and
rinsed afterwards twice with DPBS. The membranes were blocked
in tris-buffered saline (TBS; 1 M Tris, 5 M NaCl) containing 5%
skimmed milk powder (Sigma-Aldrich) for 1 h, followed by primary
antibody (mouse anti-ataxin-3, 1:2,500, clone 1H9, MAB5360,
Merck Millipore) incubation overnight at 4°C, and secondary anti-
body (IRDye 800CW goat anti-mouse IgG (H+L) 1:1,000, 926-32210,
LI-COR) incubation for 1.5 h at room temperature. Detection and
quantification of the fluorescent signal was performed using the
ODYSSEY Server software version 4.1 (LI-COR Bioscience).
Statistical analysis
Group effects
We used non-parametric procedures to analyse group effects on Nf
levels (Mann–Whitney U-tests, two-sided, Bonferroni-corrected for
multiple comparisons). To correct the group effects for age-
dependent increases of Nf levels (log-transformed) within each
cohort, we used linear models with the factors group, age and their
interaction. The optimal cut-offs for differentiating ataxic SCA3
subjects from controls by their Nf levels were determined according
to Youden’s procedure, with the cut-off allowing to benchmark Nf
levels in preataxic SCA3 subjects.
Associations between disease severity and disease progression
In ataxic subjects, we assessed the association between Nf levels
(log-transformed) and disease severity, as captured by the SARA
score, with Pearson’s correlations (two-sided test). We used partial
correlations with the covariates age, disease duration and CAG
count to adjust the association between Nfs and disease severity for
potential confounders. Prospective longitudinal SARA scores were
available for a subset of patients (n = 35; all from cohort #2;
number of longitudinal visits per subject: 2–4) allowing us to deter-
mine intraindividual disease progression as the annual change of
SARA scores (determined by intraindividual linear regression coeffi-
cients, using all available SARA scores).
Association of NfL levels with age and repeat length
We analysed the association of NfL levels with age and CAG repeat
length in SCA3 carriers with a linear model, using the pooled NfL
data of both cohorts after transforming NfL levels of cohort #2
(which were measured by homebrew Simoa) to the scale of the
Quanterix Simoa used for cohort #1. Specifically, we modelled NfL
levels (log-transformed) in all SCA3 carriers (n = 123) with the
predictors age and ATXN3 CAG repeat length, their squares and all
possible interactions, analogous to previous analyses in Hunting-
ton’s disease (Byrne et al, 2017). We centred age at 50 years (i.e.
mean age of carriers) and CAG repeat length at 68 (i.e. mean CAG
repeat length of carriers), as in analogous previous analyses (Byrne
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et al, 2017). We excluded one outlier (NfL > 700 pg/ml) to fulfil
model assumptions.
Association of NfL with time to onset in preataxic SCA3
We analysed NfL levels as a function of time to estimated onset of
ataxia in preataxic SCA3 by linear regression. For each preataxic
SCA3 subject, we individually calculated the time to the estimated
onset of ataxia based on CAG repeat count and the age at the time
of assessment, as established previously (Tezenas du Montcel et al,
2014). Hereby, the estimate based on the repeat size is adjusted for
the age which the individual has actually reached without develop-
ing ataxia; i.e., the older the preataxic subject at the time of assess-
ment, the higher the predicted age at onset. To determine the point
of time at which NfL levels become significantly increased in the
preataxic stage of SCA3, NfL levels of preataxic carriers needed to
be related to the NfL levels of controls at the same age, as NfL levels
physiologically increase with age in controls (Wilke et al, 2016).
Hence, we calculated the z-score of each SCA3 subject in relation to
the NfL distribution in controls at the same age (for a visualisation,
see Fig 3B). For this, the difference between the measured NfL level
and the NfL level estimated for controls at the same age was stan-
dardised relative to the NfL distribution in controls at this age. NfL
in controls was modelled by linear regression on the level of log-
transformed data.
Intraindividual stability of Nf levels
We assessed intraindividual stability of Nf levels by calculating the
intraclass correlation coefficient (ICC) of each analyte (model speci-
fication: two-way mixed, single-measures, absolute agreement),
using our 6-week longitudinal Nf data (log-transformed) from a
subset of subjects (n = 21) of cohort #2 where such 6-week interval
sample was available.
Sample size estimation for future treatment trials
We performed sample size estimations for future intervention trials,
which use the reduction of Nf levels towards levels observed in
healthy controls as outcome measure (Byrne et al, 2018). We esti-
mated the sample size per study arm, which would be required to
detect a given control-adjusted relative reduction of Nf levels (10–
70%) in the treatment arm, assuming that null mean change over
time occurred in the placebo arm of the trial. To this end, we based
the assumed intersubject variability in the hypothetical trial on the
measured intrasubject variability in the change of analyte levels
(from baseline to 6 weeks) in our SCA3 subjects (Fig 4). The esti-
mation further assumed equal numbers of subjects in both study
arms, a = 0.01, b = 0.01, two-tailed independent t-tests, and the use
of log-transformed analyte levels. It was performed with GPower 3.1
software (Kiel, Germany).
Murine data
We compared biomarker levels (NfL, pNfH, aggregated ataxin-3,
soluble ataxin-3) and phenotypic data between heterozygous and
wild-type animals within the same age group (i.e. animals sacrificed
at 2, 6, 12 or > 18 months), using independent t-tests (two-sided,
Bonferroni-corrected for multiple comparisons given that two
analytes were measured from each sample). Analogously, data were
compared between homozygous mutants and wild-type animals.
Throughout the manuscript, if the assumption of normality was
violated (assessed by inspection and Shapiro–Wilk test), we used
log-transformed data for the statistical analysis after ensuring that
the transformed data were normally distributed. If normality was
violated also after transformation, non-parametric tests were
applied. For parametric tests, corrections were applied if variance
differed between the groups that were compared (t-tests adjusted for
unequal variances). We analysed the data with SPSS (IBM,
version 24). We reported the effect size r of the statistical tests
wherever possible.
Data availability
All source data of this study are available in the supplementary
material of the article.
Expanded View for this article is available online.
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